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The potential negative effect of high-dose glucosamine
on the chondrocyte: comment on the article by
Carame´s et al
To the Editor:
We read with great interest the recent article by Carame´s
et al, who demonstrated that glucosamine can activate autophagy
in human chondrocytes and in mouse knee joints by inhibiting the
Akt/FoxO/mammalian target of rapamycin pathway (1). Impor-
tantly, the authors proved that intraperitoneal and oral adminis-
tration of glucosamine induced similar levels of autophagy in the
cartilage, thus providing a convenient method for inducing auto-
phagy in vivo in the future. Similarly, another study also demon-
strated the inductive effect of glucosamine on autophagy in HeLa
and COS-7 cells (2). Glucosamine has been shown to play
antiinflammatory, anticatabolic, and antiapoptotic roles in the
chondrocyte (3,4), and in the future autophagy might be identi-
fied as a mechanism mediating these effects.
However, as mentioned in reports suggesting double
roles of autophagy in disease (5), the negative effect of “auto-
phagic cell death” on chondrocytes may need to be elucidated.
After treating normal chondrocytes from SD rats with 100 mM
glucosamine for 24 hours, we observed that the cytoplasm of cells
in monolayer culture was filled with numerous vacuoles (Figure
1). When the incubation time was extended, an increasing num-
ber of chondrocytes died, which indicated that glucosamine at
high concentrations may lead to autophagic cell death. Although
we could not determine whether the cells died due to autophagy,
the results suggested that high-dose glucosamine may have a
negative effect on cell viability.
In accordance with our observations, De Mattei et al
showed that glucosamine at doses of 6.5 mg/ml (30 mM) and
25 mg/ml (116 mM) decreased cell viability in bovine carti-
lage explants by 28% and 90%, respectively (6). Moreover,
ultrastructural analysis showed that the cells in which death
was induced by glucosamine exhibited obvious vacuoles in the
cytoplasm (6). In addition, Walsh and colleagues reported that
after 4 days and 7 days of exposure to glucosamine at a dose of
4.5 mg/ml (20 mM), the DNA content of annulus fibrosus
cells was reduced by 75% and 89%, respectively (7). Therefore,
it may be imperative to place the emphasis on the concentra-
tion when treating chondrocytes with glucosamine.
In summary, although an increasing number of studies
have suggested that there may be a role for autophagy in the
treatment of arthritis, further studies, especially in the human
system, are still needed to rule out any negative effects.
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Protein kinase C mutations may contribute to lupus
through effects on T cells: comment on the article by
Belot et al
To the Editor:
Belot et al recently described 3 siblings with juvenile-
onset systemic lupus erythematosus, all of whom had a mis-
sense mutation in PRKCD, encoding protein kinase  (PKC)
(1), similar to previous observations in PKC-deficient mice in
which lupus developed (2). B cells from these siblings were
Figure 1. Photomicrographs obtained by phase-contrast microscopy,
showing the morphology of chondrocytes treated with 100 mM gluco-
samine for 24 hours, at A, lower magnification (100) and B, higher
magnification (400).
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resistant to B cell receptor– and Ca2-induced apoptosis and
demonstrated increased proliferation, also similar to B cells in
PKC-deficient mice. The development of autoimmunity is
interpreted as demonstrating that PKC is crucial in regulating
B cell tolerance and preventing self-reactivity in humans. We
would like to note that PKC activity is reduced in patients
with sporadic non-Mendelian lupus, and that this inactivation
in T cells can contribute to the development of lupus-like
autoimmunity through effects on T cell DNA methylation (3).
DNA methylation is an epigenetic mechanism that
silences gene expression by promoting a repressive chromatin
configuration that is inaccessible to transcription factors. DNA
methylation patterns are established during differentiation and
serve to suppress genes that are irrelevant or detrimental to the
functions of mature cells. The methylation patterns are then
replicated each time a cell divides, by the maintenance meth-
yltransferase DNA methyltransferase 1 (DNMT-1). DNMT-1
levels are low in resting T cells but are up-regulated in stim-
ulated T cells by signals transmitted through the ERK pathway.
Inhibiting DNA methylation in dividing T cells, either with
direct DNMT inhibitors such as 5-azacytidine or the lupus-
inducing drug procainamide, or with MEK inhibitors such as
PD98059 and U0126, alters gene expression and converts
normal antigen-specific CD4 T cells into autoreactive, cyto-
toxic, and proinflammatory T cells that are sufficient to cause
lupus-like autoimmunity in animal models (4,5). The role of
decreased T cell ERK pathway signaling in causing lupus-like
autoimmunity has been confirmed in a double-transgenic mouse
model in which dominant-negative MEK can be induced
selectively in T cells by adding doxycycline to the drinking water.
In these mice, doxycycline decreases T cell DNMT-1 levels,
demethylates DNA, activates genes normally suppressed by
DNA methylation, and causes lupus-like autoimmunity (6–8).
PKC is a multifunctional signaling molecule that plays
a crucial role in ERK pathway signaling in T cells (9). In-
hibiting T cell PKC with rottlerin or the lupus-inducing drug
hydralazine, or by transfection with a dominant-negative PKC
similarly demethylates T cell DNA methylation and alters gene
expression (3). CD4 T cells treated with hydralazine are
sufficient to cause lupus-like autoimmunity in mice (10). Taken
together, these findings indicate that inhibiting ERK pathway
signaling, through effects on PKC or downstream signaling
molecules, is sufficient to cause a lupus-like disease.
Importantly, PKC is catalytically inactivated by oxidative
damage in CD4 T cells from patients with active lupus, causing
decreased ERK pathway signaling, decreased DNMT-1 levels,
and demethylation of the same genes normally silenced by DNA
methylation (11). These observations suggest that PKC muta-
tions may contribute to lupus through effects on T cells, and the
effects on B cells seen in the patients described by Belot and
colleagues as well as in PKC-deficient mice may augment these
effects.
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Reply
To the Editor:
We thank Dr. Richardson and his colleagues for their
comments. In our study, we demonstrated that a missense
PRKCD mutation (c.1528GA; p.G510S) leads to resistance
in B cell receptor– and calcium-dependent apoptosis, resulting
in increased B cell proliferation. Our findings are consistent
with the recent demonstration that PKC is involved in an
ERK-dependent signaling pathway of B cell negative selection
through Ca2-dependent apoptosis (1). In addition, adoptive
transfer and transgenic B cell receptor (BCR) experiments in
PRKCD-knockout mice showed B cell proliferation and BCR-
dependent autoimmunity (2,3). Kuehn et al described a patient
with PRKCD mutations and demonstrated that the knockdown
of PRKCD in lymphocytes was associated with increased
proliferation of B cells but not T cells, thus seemingly empha-
sizing the major role of B cells in disease pathogenesis (4). Our
experiments did not show evidence of either a deficiency of T cell
ontogenesis or an activation anomaly of T cells. In contrast, B
cells and natural killer cells do demonstrate impaired differenti-
ation (Belot A: personal observations).
DNA demethylation is an interesting mechanism that has
been widely studied in autoimmune diseases. This process is not
restricted to CD4 T cells, having been implicated in B cells or
epithelial cells in the context of systemic lupus erythematosus
(SLE) and Sjögren’s syndrome (5,6). In accordance with the work
performed by Richardson and colleagues in this field, we can
speculate that PRKCD mutations may impact on DNMT-1 and
CD4 T cell demethylation. Thus, further “methylome-related” ex-
periments are warranted to determine whether T cell dysfunction
is relevant to the pathogenesis of this new Mendelian cause of
SLE. At this time, however, we would hold that the case remains
unproven.
LETTERS 229
